--- title: "Lineage Cell Therapeutics | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 1.725 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/286151251.md" datetime: "2026-05-12T20:18:58.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286151251.md) - [en](https://longbridge.com/en/news/286151251.md) - [zh-HK](https://longbridge.com/zh-HK/news/286151251.md) --- # Lineage Cell Therapeutics | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 1.725 M Revenue: As of FY2026 Q1, the actual value is USD 1.725 M, missing the estimate of USD 3.076 M. EPS: As of FY2026 Q1, the actual value is USD -0.03. EBIT: As of FY2026 Q1, the actual value is USD -7.998 M. #### Financial Highlights for the Three Months Ended March 31, 2026 and 2025 ##### Revenue - Total Revenues were $1.7 million for Q1 2026, an increase from $1.5 million for Q1 2025, primarily driven by collaboration revenue . - Collaboration Revenues were $1.6 million for Q1 2026, up from $1.3 million for Q1 2025 . - Royalties, License and Other Revenues were $0.15 million for Q1 2026, down from $0.232 million for Q1 2025 . ##### Operating Expenses - Total Operating Expenses increased to $9.3 million for Q1 2026, from $8.0 million for Q1 2025, representing an increase of $1.3 million . - Research and Development (R&D) Expenses were $4.2 million for Q1 2026, an increase of $1.1 million from $3.1 million for Q1 2025, mainly due to the OPC1 program, ReSonance program, and preclinical/undisclosed programs . - General and Administrative (G&A) Expenses increased to $5.1 million for Q1 2026, from $4.9 million for Q1 2025, primarily due to personnel costs . - Cost of Royalties was $0 for Q1 2026, compared to $0.036 million for Q1 2025 . ##### Profitability - Loss from Operations was - $7.6 million for Q1 2026, compared to - $6.5 million for Q1 2025 . - Net Loss Attributable to Lineage Cell Therapeutics, Inc. was - $4.8 million, or - $0.02 per share (basic) and - $0.03 per share (diluted) for Q1 2026, compared to a net loss of - $4.1 million, or - $0.02 per share (basic and diluted) for Q1 2025 . ##### Other Income (Expenses) - Total Other Income (Expenses) was $2.8 million for Q1 2026, compared to $2.4 million for Q1 2025, driven by exchange rate fluctuations and no warrant-related financing transaction costs in 2026 . ##### Cash Flow - Net Cash Used in Operating Activities was - $8.078 million for Q1 2026, compared to - $4.886 million for Q1 2025 . - Net Cash (Used in) Provided by Investing Activities was - $2.326 million for Q1 2026, compared to $1.903 million for Q1 2025 . - Net Cash Provided by Financing Activities was $5.561 million for Q1 2026, compared to $5.044 million for Q1 2025 . #### Balance Sheet Highlights (as of March 31, 2026) - Cash, Cash Equivalents, and Marketable Securities totaled $53.4 million . - Cash and Cash Equivalents were $35.939 million as of March 31, 2026, down from $40.791 million as of December 31, 2025 . - Marketable Securities were $17.442 million as of March 31, 2026, up from $14.990 million as of December 31, 2025 . - Total Assets were $109.533 million as of March 31, 2026, down from $112.584 million as of December 31, 2025 . - Total Liabilities were $56.838 million as of March 31, 2026, down from $69.238 million as of December 31, 2025 . - Total Shareholders’ Equity was $52.695 million as of March 31, 2026, up from $43.346 million as of December 31, 2025 . #### Operational Metrics - Positive 3-year Phase 1/2a clinical data for RG6501 (OpRegen®) were presented, showing sustained gains in best corrected visual acuity and partial structural restoration of the retina . - Lineage Cell Therapeutics, Inc. launched COR1, a new wholly-owned preclinical corneal endothelial disease cell therapy program, and achieved its first milestone with the AlloSCOPE™ 5D manufacturing initiative . - The company treated a second chronic spinal cord injury (SCI) patient in the OPC1 DOSED Device Safety Study and established a Scientific Advisory Board . #### Outlook / Guidance Lineage Cell Therapeutics, Inc. anticipates its $53.4 million in cash, cash equivalents, and marketable securities as of March 31, 2026, will fund operations into the second quarter of 2028 . The company plans to advance its pipeline of seven cell therapy candidates, including two clinical-stage programs, through disciplined internal spending and external partnerships . Furthermore, Lineage Cell Therapeutics, Inc. intends to progress its COR1 program into translational models and expand its Scientific Advisory Board throughout the year . ### Related Stocks - [LCTX.US](https://longbridge.com/en/quote/LCTX.US.md) ## Related News & Research - [Canaccord Genuity Reaffirms Their Buy Rating on Lineage Therap (LCTX)](https://longbridge.com/en/news/286250862.md) - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md) - [Hafnia’s Q1 2026 Financial Results Presentation to Be Held on 27 May 2026 | HAFN Stock News](https://longbridge.com/en/news/287014236.md)